 |
|
|
|
Basilea Pharmaceutica Ltd. is a biopharmaceutical company headquartered in Basel, Switzerland, listed on the SIX Swiss Exchange (SIX:BSLN). The company is focused on the discovery, development and commercialization of innovative medicines to satisfy high medical and patient needs in the hospital and specialty pharmaceutical setting. Basilea owns a broad and balanced late-stage product portfolio including novel treatments for resistant bacterial infections, systemic fungal infections, and severe skin diseases. The company’s diversified portfolio includes two commercialized drugs (alitretinoin, ceftobiprole), one investigational drug in phase III (isavuconazole) as well as substantial innovative earlier-stage programs. Alitretinoin is marketed in the United Kingdom, in Denmark and in Germany, and is approved in Finland and France. It has been recommended for approval in six additional EU Member States and is under regulatory review in Canada and Switzerland. Ceftobiprole is marketed in Canada. It is approved in Switzerland and is under review by regulatory authorities in the USA, the EU and in several other countries. Basilea has a fully integrated R&D organization and has set up commercial organizations in UK, Denmark and in Germany while it is building sales and marketing organizations to commercialize alitretinoin and to co-promote ceftobiprole in North America and in other European countries, subject to approval.
Click here to close this window |
